Development of graft-vs.-host disease-like syndrome in cyclosporine- treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity

Transplonl Recipients Transplon| Recipients With Syngenelc GVHD Without Syngenelc GVHD FIGURE 1. Nylon wool-nonadherent spleen cells from CsA-treated syngeneic marrow recipients with or without the GVHD-like syndrome, and from control, non-CsA-treated syngeneic marrow recipients were assessed for their ability to lyse Lewis, ACI, and BN, PHA or Con A blast cells labelled with 5]Cr. Effector/target ratio was 100:1. Data represent averaged (,~ _ SE) activity of animals from five separate experiments tested 5-44 d after cessation of CsA therapy. of GVHD. Fig. 1 summarizes the cytotoxic activity for all CsA-treated syngeneic transplant recipients with GVHD (documented by histology), CsA-treated syngeneic transplant recipients without any evidence of GVHD, and control (not CsA-treated) syngeneic transplant recipients. The data illustrate that nylon woolnonadherent spleen cells from CsA-treated syngeneic transplant recipients with syngeneic GVHD were capable of mediating significant lysis of Lewis, ACI, and BN target cells. In contrast, CsA-treated syngeneic transplant recipients without the GVHD-Iike syndrome, or the syngeneic transplant recipients that received only the control diluent were not capable of mounting significant lysis of these target cells.